BioGaia AB's revenue for the
three
months ended in Dec. 2023 was kr298 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was kr1,297 Mil.
BioGaia AB's Revenue per Share for the
three
months ended in Dec. 2023 was kr2.95.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr12.84.
Good Sign:
BioGaia AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of BioGaia AB was 17.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 7.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BioGaia AB's highest 3-Year average Revenue per Share Growth Rate was 47.10% per year. The lowest was -9.30% per year. And the median was 15.30% per year.
BioGaia AB Revenue Historical Data
The historical data trend for BioGaia AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Revenue distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Revenue falls into.
BioGaia AB Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,297 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (LTS:0GTN) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioGaia AB Revenue Related Terms
Thank you for viewing the detailed overview of BioGaia AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0GTN has been successfully added to your 